Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: Voller Fokus auf NurExone Biologic!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A401HW | ISIN: US98973P2002 | Ticker-Symbol:
NASDAQ
19.04.24
21:58 Uhr
1,105 US-Dollar
-0,115
-9,43 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALAUNOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ALAUNOS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,00021.03.

Aktuelle News zur ALAUNOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
01.04.Alaunos Therapeutics Inc reports results for the quarter ended in December - Earnings Summary1
01.04.Alaunos Therapeutics, Inc. - 10-K, Annual Report-
20.02.Alaunos Therapeutics, Inc. - 8-K, Current Report3
01.02.TCRT, NXT and MINM among mid-day movers5
01.02.Alaunos Therapeutics, Inc. - 8-K, Current Report3
22.01.Alaunos Therapeutics, Inc. - 8-K, Current Report2
02.01.Alaunos Therapeutics, Inc. - 8-K, Current Report7
22.12.23Alaunos Therapeutics, Inc. - 8-K, Current Report3
18.12.23Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?7
15.11.23Alaunos Therapeutics, Inc. - 8-K, Current Report1
14.11.23Alaunos Therapeutics Inc reports results for the quarter ended in September - Earnings Summary2
14.11.23Recap: Alaunos Therapeutics Q3 Earnings1
14.11.23Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?2
14.11.23Alaunos Therapeutics GAAP EPS of -$0.04 in-line5
14.11.23Alaunos Therapeutics, Inc.: Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives231TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patientshunTR®...
► Artikel lesen
14.08.23Alaunos Therapeutics, Inc.: Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives184TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patientsCompany...
► Artikel lesen
10.05.23Alaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial Results468Actively enrolling patients and manufacturing cryopreserved products for TCR-T Library Phase 1/2 trial; expect to report interim data in the third quarter of 2023Fully prepaid loan with Silicon Valley...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1